Skip to content
National Medical Products Administration (NMPA)
-
Zai Lab secures China approval for Augtyro to treat NTRK fusion-positive solid tumors
The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.